It does, however, pose questions about the capacity issues this will add to our already over-stretched primary care colleagues
(2006, N=65) tested CJC-1295 with DAC and showed dose-dependent increases in mean GH concentrations of 1.5-to-3-fold and IGF-1 increases of 1.3-to-1.9-fold that persisted for up to 28 days after a single injection [4]
PLoS ONE 9 , e112214 (2014)
CDMOs provide end-to-end services encompassing process development, analytical method development, technology transfer, clinical and commercial active pharmaceutical ingredient CDMO production, quality control, regulatory support, and supply chain management, enabling pharmaceutical and biotechnology companies to efficiently bring these therapies to market
doi: 10.1056/NEJMoa2032183 235 DahlqvistSAhlnEFilipssonKGustafssonTHirschIBTuomilehtoJet al